Miragen Therapeutics Inc (MGEN):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Miragen Therapeutics Inc (MGEN) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7157
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), Adult T-Cell Lymphoma/Leukemia, Diffuse Large-B Cell Lymphoma, Chronic Lymphocytic Leukemia, ALS, Heart Failure, Incisional Complications, Cutaneous Fibrosis, Idiopathic Pulminary Fibrosis and Other Fibrotic Indications. The pipeline development is focused on microRNA platform that regulate gene expression and influences the pathways responsible for many disease processes. Miragen is headquartered in Boulder, Colorado, the US.

Miragen Therapeutics Inc (MGEN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Equipment, Deal Details 10
Partnerships 10
Signal Genetics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Merger 11
Signal Genetics Merges with miRagen Therapeutics 11
Equity Offering 13
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 13
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 15
Signal Genetics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD10.35 Million 16
Signal Genetics Completes IPO for USD8.5 Million 17
Acquisition 18
Signal Genetics To Acquire Molecular Diagnostics Company, ChipDX 18
Miragen Therapeutics Inc – Key Competitors 19
Miragen Therapeutics Inc – Key Employees 20
Miragen Therapeutics Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 07, 2018: miRagen Therapeutics announces second quarter 2018 financial results 22
May 09, 2018: miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 24
Mar 14, 2018: miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 26
Nov 08, 2017: miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 28
Aug 11, 2017: miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 30
May 10, 2017: miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 32
Mar 31, 2017: miRagen Therapeutics Provides Corporate Update 34
Corporate Communications 35
Jan 05, 2018: miRagen Therapeutics Expands Board of Directors With Appointment of Arlene Morris 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Miragen Therapeutics Inc, Medical Equipment, Key Facts, 2017 2
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Deals By Market, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Signal Genetics Enters into Research Agreement with University of Texas MD Anderson Cancer Center 10
Signal Genetics Merges with miRagen Therapeutics 11
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 13
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 15
Signal Genetics Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD10.35 Million 16
Signal Genetics Completes IPO for USD8.5 Million 17
Signal Genetics To Acquire Molecular Diagnostics Company, ChipDX 18
Miragen Therapeutics Inc, Key Competitors 19
Miragen Therapeutics Inc, Key Employees 20
Miragen Therapeutics Inc, Subsidiaries 21

List of Figures
Miragen Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Miragen Therapeutics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Miragen Therapeutics Inc (MGEN):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Acron (AKRN):企業の財務・戦略的SWOT分析
    Summary Acron produces and commercializes mineral fertilizers. The company offers ammonium nitrate, urea, ammonia, apatite concentrate, methanol, formalin, urea-formaldehyde resins, melamine-urea-formaldehyde resins and dipping resins, cerium, lanthanum, neodymium and didymium. Its products finds ap …
  • Indoco Remedies Ltd (INDOCO):製薬・医療:M&Aディール及び事業提携情報
    Summary Indoco Remedies Ltd (Indoco Remedies) is a research-oriented pharmaceutical company that manufactures and markets formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). It has products portfolio in various therapeutic segments such as cardiovascular, central nervo …
  • Cardiff University-製薬・医療分野:企業M&A・提携分析
    Summary Cardiff University is an educational institute that provides educational and research services. The institute offers services such as undergraduate courses, post graduate courses, international courses, accommodations, and libraries, among others. It conducts research in the areas of enginee …
  • First Horizon National Corporation:企業の戦略・SWOT・財務情報
    First Horizon National Corporation - Strategy, SWOT and Corporate Finance Report Summary First Horizon National Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Sumitomo Realty & Development Co Ltd:戦略・SWOT・企業財務分析
    Sumitomo Realty & Development Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Realty & Development Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • KSK Energy Ventures Ltd (KSK):電力:M&Aディール及び事業提携情報
    Summary KSK Energy Ventures Ltd (KSKEVL), a subsidiary of KSK Energy Ltd, is a power project development company that carries out development, operations and maintenance of power projects in India. The company operates power project at multiple phases including projects in planning phase, project un …
  • Cipher Pharmaceuticals Inc (CPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company provides products such as actikerall, a topical solution indicated for the treatment of hyperkeratotic actinic keratosis; beteflam, a topical patch used for the treatment of mild to …
  • Biocartis Group NV (BCART):企業の製品パイプライン分析
    Summary Biocartis Group NV (Biocartis) operates as a molecular diagnostics company that provides personalized medicine for patients through its molecular diagnostics. The company undertakes the development of diagnostics technology platforms for multiplexed detection of bio-analytes, with oncology a …
  • Watt’s S.A.:企業の戦略・SWOT・財務情報
    Watt's S.A. - Strategy, SWOT and Corporate Finance Report Summary Watt's S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Southwestern Energy Co (SWN):企業の財務・戦略的SWOT分析
    Southwestern Energy Co (SWN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • iRhythm Technologies Inc (IRTC):企業の財務・戦略的SWOT分析
    iRhythm Technologies Inc (IRTC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Scripps Health:企業の戦略的SWOT分析
    Scripps Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Ricoh India Ltd:企業の戦略的SWOT分析
    Ricoh India Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Oncor Electric Delivery Company LLC:電力:M&Aディール及び事業提携情報
    Summary Oncor Electric Delivery Company LLC (Oncor) a subsidiary of NextEra Energy, Inc., is a regulated electricity transmission and distribution company that operates distribution and transmission systems. It provides transmission grid connections to merchant generation facilities and interconnect …
  • Assertio Therapeutics Inc (ASRT):企業の財務・戦略的SWOT分析
    Assertio Therapeutics Inc (ASRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Derma Sciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Derma Sciences Inc (Derma Sciences) is a medical devices company. It focuses on advanced wound care and traditional wound care. Its advanced wound care product portfolio includes dermagran, silverseal, alginate dressing, aquasite hydrogel, primacol hydrocolloid, hydrocell foam and primaderm …
  • Avis Budget Group, Inc.:戦略・SWOT・企業財務分析
    Avis Budget Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Avis Budget Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Claire’s Stores, Inc.:企業の戦略・SWOT・財務情報
    Claire’s Stores, Inc. - Strategy, SWOT and Corporate Finance Report Summary Claire’s Stores, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Neurolixis Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Neurolixis Inc (Neurolixis) is an early-stage biopharmaceutical company that discovers and develops novel drugs for the treatment of human central nervous system disorders. The company’s pipeline product portfolio includes NLX-112, a drug candidate intended for the treatment of L-DOPA-induce …
  • Eleison Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Eleison Pharmaceuticals LLC (Eleison Pharmaceuticals) is a drug development company that acquires, develops, and commercializes clinical stage drug candidates for orphan cancers. The company’s pipeline products include glufosfamide and inhaled lipid-complexed cisplatin. Its glufosfamide is a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆